Orthocell Ltd has released a press release.
Remplir Use in Prostate Surgery Signals Global Opportunity
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Orthocell
- Remplir™ Study Delivers Compelling 81% Success Rate
- Compelling 81% Success Rate for Remplir
- Appendix 4E & Annual Report
- Orthocell Announces First US Remplir Sales Revenue
- Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQ
Later from Orthocell
- Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery
- First Distributor signed for Remplir in $75m Canadian Market
- Another Record Revenue Quarter for Orthocell
- Trading Halt
- $30m Placement Sees Orthocell Positioned for Rapid Growth
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell